The efficacy of Cabergoline in preventing ovarian hyper stimulation in ART program

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT138808271141N7

Enrollment

130

Registered

2010-01-04

Start date

2009-08-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian hyperstimulation syndrome. Other obstetric conditions, not elsewhere classified

Interventions

Intervention 1: Gabergoline tablet (0.5 mg) daily until 6 days after oocytes retrieval. Intervention 2: Human albumin 20% infusion.

Treatment - Drugs

Gabergoline tablet (0.5 mg) daily until 6 days after oocytes retrieval

Human albumin 20% infusion

Eligibility

Sex/Gender

Female

Age

15 Years to 37 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: risk of developing OHSS, defined by the development of 20–30 follicles larger than 12 mm in diameter and retrieval of more than 20 oocytes, ovarian stimulation with long protocol Exclusion Criteria: Coasting cases, age more than 37 years, previous pelvic surgery, Intramural or submucosal myoma sizes > 5 CM, uterine polyps, Smoking, or alcohol addiction

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
OHSS occurrence rate and severity of OHSS in two groups. Timepoint: 6 days after embryos transfer(ET). Method of measurement: accordance with the Golan 5 grade system.	—

Secondary

Measure	Time frame
Pregnancy and early miscarriage rates. Timepoint: 5 week after embryo transfer until 12 gestational weeks. Method of measurement: Sonography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactArezoo Arabipour

Royan institute

arezoo.arabipoor@gmail.com+98 21 2356 2307

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026